Indometacin Atb (Indometacin)

Indometacin works by non‑selectively inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2. This inhibition blocks the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever, thereby reducing these symptoms at the site of tissue injury.

The appropriate dose of Indometacin Atb is determined by the prescribing healthcare professional based on the specific indication, severity of symptoms, and patient characteristics. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of indometacin during pregnancy and lactation has not been definitively established. It should only be used if the potential benefit outweighs the risk, and this decision must be made by a qualified healthcare provider after a thorough assessment.

To order Indometacin Atb, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Indometacin is a potent NSAID with a relatively rapid onset of action, often considered more effective for gout and certain acute inflammatory conditions compared with ibuprofen or naproxen. However, it may carry a higher risk of gastrointestinal and renal adverse effects, so clinicians balance efficacy against safety for each patient.

Indometacin Atb suppositories should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and store out of reach of children. Do not refrigerate unless specifically instructed by the supplier.

The suppository is inserted rectally, preferably after a bowel movement and before lying down. The patient should wash hands before and after insertion, lie on the left side with knees drawn toward the chest, and retain the suppository for the recommended period to allow complete absorption.

Serious risks include gastrointestinal bleeding or ulceration, severe renal impairment, hepatotoxicity, and cardiovascular events such as myocardial infarction or stroke. Patients should be monitored for signs of these conditions, and therapy should be discontinued promptly if severe adverse reactions occur.

Indometacin Atb is contraindicated in individuals with known hypersensitivity to indometacin or other NSAIDs, active gastrointestinal ulcer or bleeding, severe renal or hepatic impairment, and in patients with established cardiovascular disease where NSAID use is discouraged. A healthcare professional should evaluate suitability before prescribing.